Papers/PMID:33766084
Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial.
Trials2021The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
melatonin — decreases mean arterial pressure
Evidence strength: moderate.Finding“The mean of MAP was significantly lower in the intervention group compared with the control group post-intervention (84.80 ± 8.33 vs 91.33 ± 8.81, respectively; p = 0.01).”
Quoted verbatim from Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- two tablets once a day 1 h before bedtime, each tablet containing 3 mg net melatonin
- Population
- Adults aged 30-60 years with type 2 diabetes for more than 5 years, BMI 18.5-30 kg/m2, recruited from endocrinology clinics in Ahvaz, Iran
Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial.2021PMID:3376608410.1186/s13063-021-05174-zPermalink